Russia to launch personalized cancer vaccine next month

The initial rollout is expected to take place in the next 1-1.5 months, involving 60 melanoma patients.

The vaccine's safety and high effectiveness bring new hope to millions of cancer patients. Photo: Happiest Health.

Sharing with TASS, Mr. Alexander Gintsburg, Director of the Gamaleya Research Institute of Epidemiology and Microbiology, said that cancer patients in Russia will be treated with domestically produced vaccines in the coming months.

The patient groups for treatment have been selected and the genetic data has been fully analyzed, and researchers are ready to start treatment "within the next 1-1.5 months," Gintsburg added.

The first people to receive the personalized mRNA vaccine were 60 melanoma patients, carried out at the Herzen Moscow Oncology Institute and the Blokhin National Medical Research Center for Oncology.

The new vaccine is a personalized treatment, designed to target malignant tumors using a patient's own genetic information.

Developed with the help of artificial intelligence, messenger RNA (mRNA) technology allows vaccines to be tailored to each patient, providing more effective and targeted treatment while minimizing the risk of side effects.

In early September, Veronika Skvortsova, head of the Federal Medical -Biological Agency, announced that the new cancer vaccine had demonstrated high efficacy in preclinical testing and was ready for clinical use.

Researchers have observed a reduction in tumor size and a slowing of tumor progression, by up to 60-80% depending on the characteristics of the disease. In addition, studies have shown increased survival rates with the vaccine.

The initial target of this vaccine will be colorectal cancer. In addition, vaccine development for glioblastoma and certain types of melanoma, including ocular melanoma, is in advanced stages of development and has made significant progress.

Source: https://baohatinh.vn/nga-sap-tiem-vaccine-ung-thu-ca-nhan-hoa-trong-thang-toi-post296190.html